Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients.
Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients.
复制标题
DOI：
10.1097/wnf.0000000000000281
复制
发表时间：
2018
影响因子：
1
通讯作者：
Shinohara N
中科院分区：
文献类型：
--
作者：
Kitta T;Yabe I;Kanno Y;Higuchi M;Ouchi M;Togo M;Moriya K;Takahashi I;Matsushima M;Sasaki H;Shinohara N
补充数字内容可在文本中找到。除了运动症状，膀胱功能障碍是帕金森病（PD）患者的主要临床问题。Istradefylline是一种腺苷A2 A受体拮抗剂，已被批准用于具有磨损症状的PD患者。本研究的目的是确定长期的影响istradefylline对下尿路症状（LUTS）的PD患者。我们招募了14名男性PD患者。患者的平均年龄为73岁（61-77岁），Hoehn-Yahr分期为2（2-3），病程为9年（3-28年）。在治疗3、6和12个月后，基于给药前后的国际前列腺症状评分和膀胱过度活动症症状评分，评价了istradefylline（20 mg/d）对伴有运动并发症的PD患者LUTS的影响。运动症状在给药12个月时显著改善（运动障碍协会赞助的统一帕金森病评定量表第三部分修订版：30.0 ± 12.9 vs 13.8 ± 8.1; P < 0.01）。尿问卷的回答也有显著改善（国际前列腺症状评分，14.4 ± 7.6 vs 8.5 ± 6.8;膀胱过度活动症状评分，6.9 ± 2.8 vs 5.5 ± 3.7; P < 0.05）。用药3个月后，夜间尿频和夜间尿量百分比也有明显改善（P < 0.01）。Istradefylline不仅有效地改善PD患者的运动症状，而且还改善LUTS。
Supplemental digital content is available in the text. In addition to motor symptoms, bladder dysfunction is a major clinical issue in patients with Parkinson disease (PD). Istradefylline is adenosine A2A receptor antagonist approved for PD patients with wearing-off symptoms. The aim of this study was to determine the long-term effects of istradefylline on lower urinary tract symptoms (LUTSs) in PD patients. We enrolled 14 male PD patients. The mean age of patients was 73 years (61–77 years), the Hoehn-Yahr stage was 2 (2–3), and disease duration was 9 years (3–28 years). The effects of istradefylline (20 mg/d) on LUTSs in PD patients with motor complications after 3, 6, and 12 months of therapy were evaluated based on the International Prostate Symptom Score and Overactive Bladder Symptom Score before and after its administration. Motor symptoms significantly improved at 12 months' administration (Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale part III: 30.0 ± 12.9 vs 13.8 ± 8.1; P < 0.01). Significant improvements were also observed in the answers provided on urinary questionnaires (International Prostate Symptom Score, 14.4 ± 7.6 vs 8.5 ± 6.8; Overactive Bladder Symptom Score, 6.9 ± 2.8 vs 5.5 ± 3.7; P < 0.05). Nighttime urinary frequency and the percentage of the nocturnal urine volume also improved significantly at 3 months' administration (P < 0.01). Istradefylline effectively improved not only motor symptoms, but also LUTSs in patients with PD.